Q-omics provides the consensus-scored KRTAP5-10 profile across patient tissues and cancer cell-line models. KRTAP5-10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, KRTAP5-10 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, KRTAP5-10 RNA expression shows 13,007 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight CESC, KIRC, and BLCA as cancer lineages where KRTAP5-10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP5-10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP5-10 survival associations across molecular data types. KRTAP5-10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP5-10 RNA expression–survival associations across cancer types. High KRTAP5-10 expression shows unfavorable associations in KIRC, OV and ESCA, but favorable associations in CESC, BLCA and BRCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for KRTAP5-10 RNA expression.
This table summarizes KRTAP5-10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP5-10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP5-10 shows higher tumor expression in KIRC, THCA, LIHC, BRCA, KICH and COAD. The KIRC box plot shows higher KRTAP5-10 RNA expression in tumor versus normal tissue (log2 FC = +0.229, t-test p < 0.001).
This table shows molecular features associated with KRTAP5-10 in patient tissues and cancer cell lines. In patient samples, KRTAP5-10 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP5-10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
